TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05874947

Intervention type: DEVICE
Intervention: linear measurement
Description: Linear measurements from digital caliper ,CBCT and EOS generated digital dental models

Intervention type: DEVICE
Intervention: linear measurement
Description: Linear measurements from digital caliper ,CBCT and EOS generated digital dental models

Intervention type: DEVICE
Intervention: linear measurement
Description: Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
Study: NCT03172013

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet indices
Description: MPV, PDW
Study: NCT02051829

Intervention type: OTHER
Intervention: Comparison of the four screening score
Description: Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
Study: NCT01465087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NA-NOSE artificial olfactory system
Description: NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
Study: NCT01189214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
Study: NCT05110820

Intervention type: DIAGNOSTIC_TEST
Intervention: Automated quantitative pupillometer
Description: Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
Study: NCT01847534

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study: NCT01444326

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dairy
Description: During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy
Description: During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew).
Study: NCT04516590

Intervention type: OTHER
Description: There was no intervention in this observational study
Study: NCT02337114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
Study: NCT00425373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 40/2.5 mg
Description: Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 40/5 mg
Description: Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 80/2.5 mg
Description: Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 80/5 mg
Description: Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 40 mg
Description: Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Study: NCT02848157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: plain ropivacaine
Description: ropivacaine and normal saline equivalent doses of dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT03752359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
Study: NCT01053611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 0 ng/ml
Description: remifentanil 0 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 2 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 4 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 6 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 0 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 2 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 6 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 6 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 0 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 2 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 4 ng/ml
Study: NCT03172013

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet indices
Description: MPV, PDW

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet indices
Description: MPV, PDW
Study: NCT03330548

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleMOVE!
Description: Active comparator- telehealth treatment program for weight management and health promotion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary Rx
Description: Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
Study: NCT01383551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Becoming Parents intervention
Description: A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education.
Study: NCT03883295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: The specimens will be root canal treated conventionally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NeoMTA Plus
Description: The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
Study: NCT04319835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OnZurf Probe
Study: NCT02255162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA-mismatched stem-cell Microtransplantation
Description: Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
Study: NCT02182856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 500 µg/salbutamol sulphate 3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate 3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate 6 mg
Study: NCT01276795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Support
Description: The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutrition Support
Description: The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
Study: NCT02835391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PerClot
Description: Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Floseal, Surgicel, Surgiflo, Arista
Description: Haemostatic device for the control of bleeding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery/Diatermy
Description: Procedure for the control of bleeding
Study: NCT00807989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine/Valproate
Study: NCT00425373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 2.5 mg
Description: Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablet and 2 capsule placebos taken once daily
Study: NCT06265194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The fibromyalgia protocol applied to the patients in the study was developed specifically for fibromyalgia by Konuk, and colleagues (Konuk et al.). In addition to the article, the details of the protocol and the study sheet are presented supplementary. After a short introduction, the participants were informed about the protocol, their -consent was obtained for registration, and a visual, tactile and audio bilateral stimulus that will be used in the application was introduced.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as Usual (TAU): Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as Usual (TAU): Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
Study: NCT04570787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary bladder catheterisation
Description: Installation of Foley catheter into the urinary bladder

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary bladder catheterisation
Description: Installation of Foley catheter into the urinary bladder
Study: NCT01589289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunochromatographic HAT tests (DSD)
Description: Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Card Agglutination Trypanosoma Test
Description: Card Agglutination Trypanosoma Test on whole blood and as dilution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)
Description: TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TB 3-marker RDT (Tulip diagnostics)
Description: TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryptococcal Antigen Lateral Flow Assay (Immy)
Description: Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
Study: NCT03207386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth VIP
Description: Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
Study: NCT04315571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gore® Viatorr® Endoprosthesis with controlled expansion
Description: TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Volume Paracentesis with albumin infusion
Description: For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
Study: NCT01091324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: 60 mg, bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: 150 mg , tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo
Study: NCT02254434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
Study: NCT03925259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
Study: NCT01910246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT02264912

Intervention type: DRUG
Intervention: antiplatelet drugs - P2Y12 antagonists
Study: NCT01722422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen and saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen and saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen and saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen and saline
Study: NCT02379572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iMRI-guided surgery
Description: For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-ALA-guided surgery
Description: For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
Study: NCT02337114

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
Study: NCT02207738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microneedling radiofrequency device
Description: Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar radiofrequency
Description: bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
Study: NCT05249452

Intervention type: OTHER
Intervention: Preconditioning with azathiprine and hydroxyurea (3 months)
Description: Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
Study: NCT01226407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG200745
Description: Multiple administration (IV) over the cycles untile MTD/LTD
Study: NCT02032797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone
Study: NCT01937949

Intervention type: DEVICE
Group type: OTHER
Intervention: Custom-made Zenith® Fenestrated AAA Endovascular Graft:
Description: The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
Study: NCT02492542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHENIX USB 8.
Description: Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50\*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
Study: NCT00898950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 75mgs/day orally for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mgs/day orally for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: aspirin 900mgs QID orally for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet with lactose and excipients.
Study: NCT01235494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polarised 3 helium
Description: 1 inhalation (= 1 litre)
Study: NCT02002637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latella Knee Implant System